down arrow

IMAC Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44967K3023
USD
0.17
0.04 (33.33%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.140.20

52 Week

0.031.56
Valuation
Technical
Day's Volume

CASH

163.11 k

Shareholding (Dec 2024)

FII

0.55%

Held by 1 FIIs

DII

98.3%

Held by 1 DIIs

Promoter

0.00%

How big is IMAC Holdings, Inc.?

22-Jun-2025

As of Jun 18, IMAC Holdings, Inc. has a market capitalization of 0.17 million, categorizing it as a Micro Cap company, with recent net sales of 0.08 million and a net profit of -6.29 million over the last four quarters. Shareholder's funds are -6.39 million, and total assets are valued at 1.59 million.

Market Cap: As of Jun 18, IMAC Holdings, Inc. has a market capitalization of 0.17 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.08 million, while the sum of Net Profit is -6.29 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, Shareholder's Funds amount to -6.39 million, and Total Assets are valued at 1.59 million.

Read More

What does IMAC Holdings, Inc. do?

22-Jun-2025

IMAC Holdings, Inc. provides movement and orthopedic therapies and minimally invasive procedures in the Pharmaceuticals & Biotechnology sector. It has a market cap of $0.17 million and reported a net profit loss of $2 million as of December 2024.

Overview: <BR>IMAC Holdings, Inc. is a provider of movement and orthopedic therapies and minimally invasive procedures in the Pharmaceuticals & Biotechnology industry, operating in the micro-cap market.<BR><BR>Financial Snapshot: <BR>Net Profit: -2 Million (Quarterly Results - Dec 2024) <BR>Market Cap: USD 0.17 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.08 <BR>Return on Equity: 98.50% <BR>Price to Book: -0.03<BR><BR>Contact Details: <BR>Address: 1605 Westgate Cir, BRENTWOOD TN: 37027 <BR>Fax: 1 302 6745266 <BR>Website: https://imacregeneration.com/

Read More

Is IMAC Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of February 10, 2025, IMAC Holdings, Inc. is considered overvalued with a negative price-to-book value and an EV to EBITDA ratio indicating insufficient earnings, while its stock has plummeted 97.59% over the past year, contrasting sharply with its peers and the overall market.

As of 10 February 2025, the valuation grade for IMAC Holdings, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued given its negative price-to-book value of -0.02 and an EV to EBITDA ratio of 0.06, which suggests that it is not generating sufficient earnings relative to its enterprise value. Additionally, the return on capital employed (ROCE) is exceptionally high at 81.52%, but this is misleading due to the company's negative book value.<BR><BR>In comparison to its peers, IMAC Holdings, Inc. shows a stark contrast with GeneDx Holdings Corp., which has a P/E ratio of -63.58, and Aveanna Healthcare Holdings, Inc. with a P/E of 21.61, both of which are in a risky valuation category. The overall market performance has been dismal, with the stock down 97.59% over the past year compared to a 10.26% increase in the S&P 500. This further reinforces the conclusion that IMAC Holdings, Inc. is overvalued in its current state.

Read More

Is IMAC Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, IMAC Holdings, Inc. shows a neutral trend with mixed technical indicators, underperforming the S&P 500 significantly, suggesting a cautious investment approach.

As of 4 September 2025, the technical trend for IMAC Holdings, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators: the MACD shows mildly bullish signals on both weekly and monthly time frames, while the RSI is bullish monthly but shows no signal weekly. The Bollinger Bands indicate mildly bullish weekly but mildly bearish monthly trends. Daily moving averages are mildly bearish, and KST is bullish weekly but bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives. The OBV is mildly bullish monthly but shows no trend weekly. <BR><BR>In terms of performance, IMAC has significantly underperformed compared to the S&P 500, with a year-to-date return of -94.33% versus the S&P 500's 12.22%. Overall, the mixed signals suggest a cautious approach is warranted.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.19

stock-summary
Return on Equity

81.92%

stock-summary
Price to Book

-0.03

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
127.88%
0%
127.88%
6 Months
240.0%
0%
240.0%
1 Year
-85.95%
0%
-85.95%
2 Years
-92.98%
0%
-92.98%
3 Years
-18.85%
0%
-18.85%
4 Years
-99.52%
0%
-99.52%
5 Years
-84.82%
0%
-84.82%

IMAC Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-67.15%
EBIT Growth (5y)
-3.59%
EBIT to Interest (avg)
-7.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
1.92
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.02
EV to EBIT
0.06
EV to EBITDA
0.06
EV to Capital Employed
0.05
EV to Sales
-0.35
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
81.52%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.15%)

Foreign Institutions

Held by 1 Foreign Institutions (0.55%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.55% vs 4.35% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.10",
          "chgp": "9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-2.20",
          "chgp": "4.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-1,459,267.30%",
          "chgp": "1,45,926.73%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.08% vs 44.92% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-2.50",
          "chgp": "-120.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.10",
          "chgp": "600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.30",
          "val2": "-6.50",
          "chgp": "3.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-78,046.70%",
          "val2": "0.00%",
          "chgp": "-7,804.67%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-2.10
9.52%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.10
-2.20
4.55%
Operating Profit Margin (Excl OI)
0.00%
-1,459,267.30%
1,45,926.73%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 4.55% vs 4.35% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-5.50
-2.50
-120.00%
Interest
0.70
0.10
600.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.30
-6.50
3.08%
Operating Profit Margin (Excl OI)
-78,046.70%
0.00%
-7,804.67%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 3.08% vs 44.92% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About IMAC Holdings, Inc. stock-summary
stock-summary
IMAC Holdings, Inc.
Pharmaceuticals & Biotechnology
IMAC Holdings, Inc. is a provider of movement and orthopedic therapies and minimally invasive procedures performed through its regenerative and rehabilitative medical treatments. The Company operates innovative medical advancements and care (IMAC) regeneration centers, which combines life science with medical care for movement restricting diseases and conditions. Its outpatient medical clinics focuses on treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. The Company’s outpatient medical clinics provides minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It partners with athletes and operates Ozzie Smith IMAC Regeneration Centers, David Price IMAC Regeneration Centers, Mike Ditka IMAC Regeneration Centers and Tony Delk IMAC Regeneration Center. The Company owns and manages approximately 15 outpatient clinics.
Company Coordinates stock-summary
Company Details
1605 Westgate Cir , BRENTWOOD TN : 37027
stock-summary
Tel:
stock-summary
https://imacregeneration.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."